by Richard Daverman, PhD
March 18, 2014 -- Sagent Pharmaceuticals will invest $30 million to build a second production line at its China production plant. At full capacity, the Chengdu facility will be able to supply 25% of its annual product needs. In general, Sagent uses partners to produce its portfolio of injectables products, but it spent $25 million last year to buy out its China JV partner and bring the Chengdu operation entirely in-house, the only production facility Sagent owns. More details....
Stock Symbol: (NSDQ: SGNT)
Help employers find you! Check out all the jobs and post your resume.
